Home › Companies › TARA

Protara Therapeutics

Market cap $143M 61.6M shares (10-Q, Nov 3, 2026) × $2.32 close Nov 17, 2026

Most recent annual filing: 2026-03-10

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. IV Choline Chloride Ph3 interim4Q 2026IV Choline Chloride Ph3 interim, 4Q 2026, material
  2. TARA-002 NMIBC enrollment done4Q 2026TARA-002 NMIBC enrollment done, 4Q 2026, notable
  3. TARA-002 Lymphatic Malformations enrollment done1Q 2027TARA-002 Lymphatic Malformations enrollment done, 1Q 2027, routine
  4. TARA-002 BLA filing2H 2027TARA-002 BLA filing, 2H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Capital (as filed)

Cash
$25.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$102M Sep 30, 2026
Long-term investments
$16.0M Sep 30, 2026
Operating cash flow
−$18.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$143M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Protara Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy speculative Protara Therapeutics (TARA): Scientific Deep Dive for Lead and Pipeline Products Downside cushioned by fortress balance sheet and cash runway into 2028, with near-term upside from Q1 2026 BCG-Unresponsive data readout and PRV optionality from LM program.
  2. Buy speculative UPDATE: Protara Therapeutics (TARA) - ASCO GU Update ASCO GU data showed 33.3% 12-month CR clearing the FDA's ~30% regulatory floor with pristine safety profile; thesis intact with downside still protected by cash runway into 2028.
  3. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - FY25 Earnings $198M cash position removes financing overhang ahead of critical inflection points, but the repurposed biological pipeline carries inherent speculative risk.
  4. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The Warrant Trigger Trips 68.0% six-month CR across 25 patients confirms data integrity; warrant mechanics and authorized-share expansion are flags to watch but do not break the thesis.
  5. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - Q1 2026 Status Check LM BLA on 2H 2027 timeline is most concrete the PRV thesis has been, but faster-than-modeled cash burn and CEO's expanded 10b5-1 selling plan are new watch items.
  6. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The ATM Goes Live Clinical thesis unchanged but $100M ATM with TD Cowen means the 'no dilutive raise' selling point from the original BUY case no longer applies.
  7. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The BCG-Naïve 12-Month Holds BCG-Naïve 55% 12-month CR with 91.7% nine-to-twelve-month durability fully underwrites ADVANCED-3 design; sell-off driven by ATM overhang, not clinical deterioration.
  8. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The CMO Walks on Warrant Deadline Day CMO departure is a flag not a fire, but combined with ATM, CEO selling plan, and warrants expiring worthless, governance/financing noise has been louder than clinical signal for six weeks.
  9. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - ADVANCED-3 Stops Being a Phase 3 ADVANCED-3 redesigned from registrational Phase 3 to open-label exploratory trial, reducing the NMIBC thesis to a single-arm cohort; clinical data unchanged but structural bull case narrowed.
  10. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - Buying the Factory Acquiring Novex de-risks CMC manufacturing, but STARBORN-1 slipped a quarter, BLA language softened, and stock trades near cash value suggesting market expects dilution.
  11. Speculative buy speculative UPDATE: Protara Therapeutics (TARA) - The Anchor Holder Is Gone Janus Henderson fully exited its 9.6% anchor position during the slide, a negative conviction signal, but supply overhang is now cleared and stock still trades near cash value ahead of Q4 catalysts.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)